Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Prometheus Biosciences stock
Learn how to easily invest in Prometheus Biosciences stock.
Prometheus Biosciences Inc is a biotechnology business based in the US. Prometheus Biosciences shares (RXDX) are listed on the NASDAQ and all prices are listed in US Dollars. Prometheus Biosciences employs 24 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Prometheus Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RXDX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Prometheus Biosciences stock price (NASDAQ: RXDX)Use our graph to track the performance of RXDX stocks over time.
Prometheus Biosciences shares at a glance
|Latest market close||$34.18|
|52-week range||$16.11 - $40.49|
|50-day moving average||$33.93|
|200-day moving average||$26.58|
|Wall St. target price||$47.14|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.13|
Buy Prometheus Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Prometheus Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Prometheus Biosciences price performance over time
|1 week (2022-01-20)||0.12%|
|1 month (2021-12-28)||-7.85%|
|3 months (2021-10-28)||17.54%|
|6 months (2021-07-28)||62.22%|
|1 year (2021-01-24)||N/A|
|2 years (2020-01-24)||N/A|
|3 years (2019-01-24)||N/A|
|5 years (2017-01-24)||N/A|
Prometheus Biosciences financials
|Revenue TTM||$2.6 million|
|Gross profit TTM||$-17,918,000|
|Return on assets TTM||-32.93%|
|Return on equity TTM||-176.66%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
Prometheus Biosciences share dividends
We're not expecting Prometheus Biosciences to pay a dividend over the next 12 months.
You may also wish to consider:
- Vedanta (VEDL.US) (9.05% forward annual dividend yield)
Have Prometheus Biosciences's shares ever split?
Prometheus Biosciences's shares were split on a 1:100 basis on 31 October 2013. So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Prometheus Biosciences shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for Prometheus Biosciences shares which in turn could have impacted Prometheus Biosciences's share price.
Prometheus Biosciences overview
Prometheus Biosciences, Inc. , a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc.
Prometheus Biosciences in the news
Earnings playbook: A complete guide to this week's reports, including the first of tech
Markets are expected to remain on edge as the Fed meets in the week ahead
Netflix quietly admits streaming competition is eating into growth
Frequently asked questionsWhat percentage of Prometheus Biosciences is owned by insiders or institutions?
Currently 34.818% of Prometheus Biosciences shares are held by insiders and 68.719% by institutions. How many people work for Prometheus Biosciences?
Latest data suggests 24 work at Prometheus Biosciences. When does the fiscal year end for Prometheus Biosciences?
Prometheus Biosciences's fiscal year ends in December. Where is Prometheus Biosciences based?
Prometheus Biosciences's address is: 9410 Carroll Park Drive, San Diego, CA, United States, 92121 What is Prometheus Biosciences's ISIN number?
Prometheus Biosciences's international securities identification number is: US74349U1088
More guides on Finder
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Stocks are dropping; 3 rules for buying on the dip
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market has lost $1.5 trillion in value — time to buy?
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin tumbles past $40,000, altcoins follow
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s Pavia plot sale shows land rush is on in the metaverse
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart dives deep into the metaverse with crypto and NFTs
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump has an NFT — what to know before you buy
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Vigorus (VIS) price prediction
Read our expert analysis on Vigorus and how the token will perform in the future.
Dogecoin jumps 10% on word you can use it to buy Tesla merch
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
Thursday’s top U.S. stocks: Taiwan Semiconductor Manufacturing Company Ltd. (TSM ↑8.4%), Lam Research Corporation (LRCX ↑6.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Ask an Expert